PERBANDINGAN KARAKTERISTIK KLINIKOPATOLOGIS ANTARA ADENOKARSINOMA KOLOREKTAL MUCINOUS DAN NON-MUCINOUS DI MAKASSAR TAHUN 2021-2023
Abstract
ABSTRAK
Adenokarsinoma kolorektal terdiri dari dua subtipe utama, yaitu mucinous dan non-mucinous, dengan karakteristik klinikopatologis yang berbeda. Memahami perbedaan ini penting untuk menentukan prognosis dan pendekatan terapi yang tepat. Penelitian ini bertujuan mengevaluasi perbedaan klinikopatologis, termasuk grading Tumor Infiltrating Lymphocytes (TILs), antara adenokarsinoma mucinous dan non-mucinous. Studi cross-sectional ini melibatkan 24 pasien adenokarsinoma kolorektal di Rumah Sakit Dr. Wahidin Sudirohusodo, Makassar (2021-2023). Sebanyak 12 pasien dengan adenokarsinoma mucinous dan 12 pasien dengan adenokarsinoma non-mucinous dianalisis. Uji Chi-square digunakan untuk menilai perbedaan grading TILs dan variabel klinikopatologis lainnya, dengan p < 0,05 dianggap signifikan. Grading TILs secara signifikan lebih tinggi pada adenokarsinoma non-mucinous dibandingkan mucinous (p = 0,002). Tidak terdapat perbedaan signifikan pada usia (p = 0,640), jenis kelamin (p = 0,667), invasi limfovaskular (p = 1,000), metastasis nodus limfatik (p = 0,372), tumor budding (p = 0,372), pT (p = 0,457), dan lokasi tumor (p = 0,148). Grading TILs yang lebih tinggi pada adenokarsinoma non-mucinous menunjukkan respons imun yang lebih kuat. Hasil ini dapat membantu personalisasi strategi terapi pada adenokarsinoma kolorektal.
Kata Kunci: Adenokarsinoma kolorektal, mucinous, non-mucinous, Tumor Infiltrating Lymphocytes (TILs), klinikopatologi.
ABSTRACT
Colorectal adenocarcinoma consists of two main subtypes: mucinous and non-mucinous, with distinct clinicopathological characteristics. Understanding these differences is important for determining prognosis and appropriate therapeutic approaches. This study aims to evaluate the clinicopathological differences, including Tumor Infiltrating Lymphocytes (TILs) grading, between mucinous and non-mucinous colorectal adenocarcinoma. This cross-sectional study involved 24 colorectal adenocarcinoma patients at Dr. Wahidin Sudirohusodo Hospital, Makassar (2021-2023). Twelve patients with mucinous adenocarcinoma and 12 with non-mucinous adenocarcinoma were analyzed. Chi-square tests were used to assess differences in TILs grading and other clinicopathological variables, with p < 0.05 considered significant. TILs grading was significantly higher in non-mucinous adenocarcinoma compared to mucinous (p = 0.002). No significant differences were found in age (p = 0.640), gender (p = 0.667), lymphovascular invasion (p = 1.000), lymph node metastasis (p = 0.372), tumor budding (p = 0.372), pT classification (p = 0.457), and tumor location (p = 0.148). Higher TILs grading in non-mucinous adenocarcinoma indicates a stronger immune response. These findings may assist in personalizing therapeutic strategies for colorectal adenocarcinoma patients.
Keywords: Colorectal adenocarcinoma, mucinous, non-mucinous, Tumor Infiltrating Lymphocytes (TILs), clinicopathological analysis.
Downloads
References
1. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14(10). doi:10.1016/j.tranon.2021.101174
2. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188. doi:10.1111/his.13975
3. Verhulst J, Ferdinande L, Demetter P, Ceelen W. Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis. J Clin Pathol. 2012;65(5):381-388. doi:10.1136/jclinpath-2011-200340
4. Lan YT, Chang SC, Lin PC, et al. Clinicopathological and Molecular Features of Colorectal Cancer Patients With Mucinous and Non-Mucinous Adenocarcinoma. Front Oncol. 2021;11. doi:10.3389/fonc.2021.620146
5. Nguyen B, Sanchez-Vega F, Fong CJ, et al. The genomic landscape of carcinomas with mucinous differentiation. Sci Rep. 2021;11(1):9478. doi:10.1038/s41598-021-89099-2
6. O’Connell E, Reynolds IS, McNamara DA, Burke JP, Prehn JHM. Resistance to Cell Death in Mucinous Colorectal Cancer—A Review. Cancers (Basel). 2021;13(6):1389. doi:10.3390/cancers13061389
7. Mekenkamp LJM, Heesterbeek KJ, Koopman M, et al. Mucinous adenocarcinomas: Poor prognosis in metastatic colorectal cancer. Eur J Cancer. 2012;48(4):501-509. doi:10.1016/j.ejca.2011.12.004
8. O’Connell E, Reynolds IS, Salvucci M, McNamara DA, Burke JP, Prehn JHM. Mucinous and non-mucinous colorectal cancers show differential expression of chemotherapy metabolism and resistance genes. Pharmacogenomics J. 2021;21(4):510-519. doi:10.1038/s41397-021-00229-5
9. Huang A, Yang Y, Shi JY, et al. Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer. World J Gastrointest Surg. 2021;13(12):1567-1583. doi:10.4240/wjgs.v13.i12.1567
10. Leopoldo S, Lorena B, Cinzia A, et al. Two Subtypes of Mucinous Adenocarcinoma of The Colorectum: Clinicopathological and Genetic Features. Ann Surg Oncol. 2008;15(5):1429-1439. doi:10.1245/s10434-007-9757-1
11. Huang A, Yang Y, Sun Z, et al. Clinicopathological characteristics and outcomes of colorectal mucinous adenocarcinoma: a retrospective analysis from China. Front Oncol. 2024;14. doi:10.3389/fonc.2024.1335678
12. Luo C, Cen S, Ding G, Wu W. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. Cancer Commun. 2019;39(1):1-13. doi:10.1186/s40880-019-0361-0
13. Hugen N, Brown G, Glynne-Jones R, de Wilt JHW, Nagtegaal ID. Advances in the care of patients with mucinous colorectal cancer. Nat Rev Clin Oncol. 2016;13(6):361-369. doi:10.1038/nrclinonc.2015.140
14. Antohe M, Nedelcu RI, Nichita L, et al. Tumor infiltrating lymphocytes: The regulator of melanoma evolution (Review). Oncol Lett. 2019;17(5):4155-4161. doi:10.3892/ol.2019.9940
15. Lei X, Lei Y, Li JK, et al. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126-133. doi:10.1016/j.canlet.2019.11.009
16. Fuchs TL, Sioson L, Sheen A, et al. Assessment of Tumor-Infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma A Study of 1034 Patients.; 2019. www.ajsp.com
17. Woo SR, Fuertes MB, Corrales L, et al. STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors. Immunity. 2014;41(5):830-842. doi:10.1016/j.immuni.2014.10.017
18. Reynolds IS, O’Connell E, Fichtner M, et al. Mucinous adenocarcinoma is a pharmacogenomically distinct subtype of colorectal cancer. Pharmacogenomics J. 2020;20(3):524-532. doi:10.1038/s41397-019-0137-6
19. Luo C, Cen S, Ding G, Wu W. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. Cancer Commun. 2019;39(1):1-13. doi:10.1186/s40880-019-0361-0
20. Pilard C, Ancion M, Delvenne P, Jerusalem G, Hubert P, Herfs M. Cancer immunotherapy: it’s time to better predict patients’ response. Br J Cancer. 2021;125(7):927-938. doi:10.1038/s41416-021-01413-x
21. Gubin MM, Vesely MD. Cancer Immunoediting in the Era of Immuno-Oncology.
22. Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILS) in breast cancer: Recommendations by an International TILS Working Group 2014. Annals of Oncology. 2015;26(2):259-271. doi:10.1093/annonc/mdu450
23. Passardi A, Canale M, Valgiusti M, Ulivi P. Immune checkpoints as a target for colorectal cancer treatment. Int J Mol Sci. 2017;18(6). doi:10.3390/ijms18061324
24. Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2019;234(6):8509-8521. doi:10.1002/jcp.27782
25. Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111-1122. doi:10.1080/21645515.2019.1571892
26. Giovannucci E. Molecular Biologic and Epidemiologic Insights for Preventability of Colorectal Cancer. J Natl Cancer Inst. 2022;114(5):645-650. doi:10.1093/jnci/djab229
27. Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. Cancers (Basel). 2021;13(9):2025. doi:10.3390/cancers13092025
28. Abancens M, Bustos V, Harvey H, McBryan J, Harvey BJ. Sexual Dimorphism in Colon Cancer. Front Oncol. 2020;10. doi:10.3389/fonc.2020.607909
29. Gaghana L, Miskad U, Cangara MH, et al. The Relationship Between Expression of EpCAM Cancer Stem Cell Marker with Histopathological Grading, Lymphovascular Invasion, and Metastases in Colorectal Adenocarcinoma. Asian Pacific Journal of Cancer Prevention. 2023;24(3):929-934. doi:10.31557/APJCP.2023.24.3.929
30. Menon G, Recio-Boiles A, Lotfollahzadeh S, Cagir B. Colon Cancer. StatPearls; 2024.
31. Yuan Y. Spatial Heterogeneity in the Tumor Microenvironment. Cold Spring Harb Perspect Med. 2016;6(8):a026583. doi:10.1101/cshperspect.a026583
32. Triantafillidis JK, Vagianos C, Malgarinos G. Colonoscopy in Colorectal Cancer Screening: Current Aspects. Indian J Surg Oncol. 2015;6(3):237-250. doi:10.1007/s13193-015-0410-3
33. Labianca R, Beretta GD, Kildani B, et al. Colon cancer. Crit Rev Oncol Hematol. 2010;74(2):106-133. doi:10.1016/j.critrevonc.2010.01.010
34. Wang X, Cao Y, Ding M, et al. Oncological and prognostic impact of lymphovascular invasion in Colorectal Cancer patients. Int J Med Sci. 2021;18(7):1721-1729. doi:10.7150/ijms.53555
35. Aktekin A, Özkara S, Gürleyik G, Odabaşi M, Müftüoğlu T, Sağlam A. The Factors Effecting Lymphovascular Invasion in Adenocarcinoma of the Colon and Rectum. Indian Journal of Surgery. 2015;77:314-318. doi:10.1007/s12262-013-0816-5
36. Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Modern Pathology. 2017;30(9):1299-1311. doi:10.1038/modpathol.2017.46
Copyright (c) 2024 Medika Alkhairaat: Jurnal Penelitian Kedokteran dan Kesehatan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with Medika Alkhairaat : Jurnal Penelitian Kedokteran dan Kesehatan agree to the following terms:
1. Authors retain copyright and grant Journal Medika Alkhairaat right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/) that allows others to remix, adapt, build upon the work non-commercially with an acknowledgement of the work’s authorship and initial publication in Journal Medika Alkhairaat.
2. Authors are permitted to copy and redistribute the journal’s published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in Journal Medika Alkhairaat.
